Vaxcyte, Inc. $PCVX Shares Newly Bought by VIRGINIA RETIREMENT SYSTEMS ET Al

VIRGINIA RETIREMENT SYSTEMS ET Al bought a new position in Vaxcyte, Inc. (NASDAQ:PCVX) in the 3rd quarter, according to its most recent Form 13F filing with the SEC. The institutional investor bought 29,000 shares of the company’s stock, valued at approximately $1,650,000.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in the company. China Universal Asset Management Co. Ltd. boosted its position in shares of Vaxcyte by 18.1% in the third quarter. China Universal Asset Management Co. Ltd. now owns 27,151 shares of the company’s stock worth $1,539,000 after purchasing an additional 4,170 shares during the period. BG Investment Services LLC purchased a new stake in shares of Vaxcyte in the third quarter worth $1,075,000. Manchester Capital Management LLC purchased a new stake in shares of Vaxcyte in the third quarter worth $47,000. Sterling Capital Management LLC raised its position in shares of Vaxcyte by 221.6% during the 3rd quarter. Sterling Capital Management LLC now owns 3,775 shares of the company’s stock valued at $215,000 after purchasing an additional 2,601 shares during the period. Finally, Inspire Investing LLC bought a new stake in shares of Vaxcyte during the 3rd quarter valued at $453,000. Institutional investors own 96.78% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of brokerages recently issued reports on PCVX. Bank of America lowered their price target on Vaxcyte from $133.00 to $130.00 and set a “buy” rating for the company in a research report on Monday, September 28th. Guggenheim boosted their price objective on shares of Vaxcyte from $116.00 to $125.00 and gave the company a “buy” rating in a research report on Monday, October 5th. Cantor Fitzgerald reiterated an “overweight” rating and set a $120.00 price objective on shares of Vaxcyte in a research report on Monday, October 12th. BTIG Research reissued a “buy” rating and issued a $89.00 target price on shares of Vaxcyte in a research note on Monday, October 5th. Finally, Zacks Research upgraded shares of Vaxcyte from a “strong sell” rating to a “hold” rating in a report on Wednesday, August 12th. Seven investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $110.50.

Vaxcyte Stock Up 8.0%

Shares of NASDAQ:PCVX opened at $65.68 on Thursday. The business’s 50-day moving average is $61.64 and its 200 day moving average is $57.16. Vaxcyte, Inc. has a 1 year low of $39.87 and a 1 year high of $90.75.

Vaxcyte (NASDAQ:PCVX) last announced its quarterly earnings results on Wednesday, November 4th. The company reported ($1.99) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($2.11) by $0.12. During the same quarter in the previous year, the company earned ($1.56) EPS. On average, equities research analysts predict that Vaxcyte, Inc. will post -7.47 EPS for the current year.

Insiders Place Their Bets

In other Vaxcyte news, EVP Jim Wassil sold 2,250 shares of Vaxcyte stock in a transaction dated Monday, November 2nd. The stock was sold at an average price of $60.90, for a total transaction of $137,025.00. Following the completion of the sale, the executive vice president directly owned 145,435 shares of the company’s stock, valued at $8,856,991.50. The trade was a 1.52% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CAO Elvia Cowan sold 3,000 shares of the firm’s stock in a transaction that occurred on Monday, November 2nd. The shares were sold at an average price of $60.92, for a total value of $182,760.00. Following the completion of the sale, the chief accounting officer directly owned 27,860 shares of the company’s stock, valued at $1,697,231.20. This represents a 9.72% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last 90 days, insiders sold 50,692 shares of company stock worth $4,032,875. 3.30% of the stock is owned by insiders.

Vaxcyte Company Profile

Vaxcyte, Inc (NASDAQ: PCVX) is a clinical-stage biotechnology company focused on developing vaccines designed to protect against serious bacterial diseases. The company is headquartered in San Carlos, California, and uses its proprietary cell-free protein synthesis and conjugation technologies to develop vaccine candidates intended to provide broad and durable immune protection.

Vaxcyte’s lead programs target pneumococcal disease, an infection caused by Streptococcus pneumoniae.